Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology · 2024
Doxorubicin-related cardiotoxicity: review of fundamental pathways of cardiovascular system injury.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Avagimyan Ashot, Pogosova Nana, Kakturskiy Lev, Sheibani Mohammad, Challa Abhiram, Kogan Eugenia, Fogacci Federica, Mikhaleva Liudmila, Vandysheva Rositsa, Yakubovskaya Marianna, Faggiano Andrea, Carugo Stefano, Urazova Olga, Jahanbin Behnaz, Lesovaya Ekaterina, Polana Srujana, Kirsanov Kirill, Sattar Yasar, Trofimenko Artem, Demura Tatiana, Saghazadeh Amene, Koliakos George, Shafie Davood, Alizadehasl Azin, Cicero Arrigo, Costabel Juan Pablo, Biondi-Zoccai Giuseppe, Ottaviani Giulia, Sarrafzadegan Nizal
Аннотация
Over the years, advancements in the field of oncology have made remarkable strides in enhancing the efficacy of medical care for patients with cancer. These modernizations have resulted in prolonged survival and improved the quality of life for these patients. However, this progress has also been accompanied by escalation in mortality rates associated with anthracycline chemotherapy. Anthracyclines, which are known for their potent antitumor properties, are notorious for their substantial cardiotoxic potential. Remarkably, even after 6 decades of research, a conclusive solution to protect the cardiovascular system against doxorubicin-induced damage has not yet been established. A comprehensive understanding of the pathophysiological processes driving cardiotoxicity combined with targeted research is crucial for developing innovative cardioprotective strategies. This review seeks to explain the mechanisms responsible for structural and functional alterations in doxorubicin-induced cardiomyopathy.